Roivant Sciences Ltd. Common Shares Q1 2025 Earnings Recap

ROIV Q1 2025 August 11, 2025

Get alerts when ROIV reports next quarter

Roivant posted a quiet but strategic quarter with notable advancements in its pipeline, setting the stage for an active fall and potential game-changing data from brepocitinib.

Earnings Per Share Beat

$-0.18 vs $-0.25 est.

+27.9% surprise

Revenue Miss

2170000 vs 7300867 est.

-70.3% surprise

Market Reaction

1-Day -1.76%

5-Day -1.67%

30-Day +7.94%

See ROIV alongside your other holdings

Add to your portfolio — free

Key Takeaways

Completed pivotal trial enrollment for brepocitinib; registrational data expected in the second half of 2025.
Launched a new $500 million share repurchase program after successfully completing a $1.5 billion buyback, reducing share count by over 15%.
Progressing clinical trials for IMVT-1402, with enrollment underway in significant indications including Grave's disease and dermatomyositis.
Ongoing LNP litigation with Moderna and others, with trial scheduled for March 2026.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ROIV on AllInvestView.